 |
市場調査レポート
商品コード
971977
手掌多汗症の米国市場：洞察、疫学、および2030年までの予測Palmar Hyperhidrosis Market Insights, Epidemiology, and Market Forecast - 2030 (US) |
||||||
| 手掌多汗症の米国市場：洞察、疫学、および2030年までの予測 |
|
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 65 Pages
納期: 2～10営業日
|
米国における手掌多汗症の市場規模は、2017年～2030年の調査期間に大幅なCAGRで拡大すると予想されています。世界市場は米国が大幅に占めており、2017年には2億4,610万米ドルとなりました。
米国の診断された手掌多汗症の症例数は、2017年に140万7,107例となっています。そのうち77万3,909例が重症で、63万3,198例が非重症でした。
当レポートは、米国の手掌多汗症市場について調査しており、疾患の概要および疫学、市場規模や予測、動向、成長要因および課題、機会、新たな治療法および開発活動、アンメットニーズなどの情報を提供しています。
DelveInsight's 'Palmar Hyperhidrosis Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends of Palmar Hyperhidrosis in the United States.
The Palmar Hyperhidrosis market report provides analysis regarding current treatment practices, an emerging drug, like Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), potential therapies, market share of the individual therapies, historical, current and forecasted Palmar Hyperhidrosis market size from 2017 to 2030 for the United States.
The report also covers current Palmar Hyperhidrosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Study Period: 2017-2030
Palmar hyperhidrosis (PH) is a relatively common condition characterized by excessive hand sweating beyond normal thermoregulatory needs. Etiologically, the disorder can be primary (idiopathic) or secondary due to an underlying cause. Primary PH tends to arise in childhood or adolescence and usually persists throughout life. Despite its unknown origin, it is attributed to localized sympathetic hyperactivity on otherwise normal eccrine sweat glands, mainly triggered by emotional or thermal stimuli. Secondary PH occurs as a result of underlying pathology or medication use.
Inconvenience is experienced by patients with PH when there is a direct interference with activities involving the hands. Direct interference of sweating impacts work or school life due to difficulties with using computer keyboards, holding objects, working with paper documents, or giving handshakes.
This chapter covers the details of conventional and current medical therapies available in the Palmar Hyperhidrosis market to treat the condition. It also provides the country-wise Palmar Hyperhidrosis treatment guidelines for the United States.
DelveInsight's Palmar Hyperhidrosis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Palmar Hyperhidrosis treatment algorithms and treatment guidelines in the US.
The Palmar Hyperhidrosis epidemiology chapters provide insights about historical and current Palmar Hyperhidrosis patient pool and forecasted trends for US. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Palmar Hyperhidrosis Palmar Hyperhidrosis epidemiology is segmented by Diagnosed Prevalent Cases of Palmar Hyperhidrosis, Diagnosed cases of Palmar Hyperhidrosis, cases of Palmar Hyperhidrosis by Age, and Severe cases of Palmar Hyperhidrosis. The report includes a thorough analysis of all segmentations.
In the US, the cases of Hyperhidrosis were 15,634,521 in 2017. Moreover, the total diagnosed prevalent cases of Palmar Hyperhidrosis in the United States were found to be 1,407,107 in 2017.
According to DelveInsight's analysis, In the United States, the highest number of Palmar Hyperhidrosis was reported to be among individuals above 18 years of age.
In the United States, out of all the total prevalent cases reported 773,909 severe and 633,198 non-severe cases for Palmar Hyperhidrosis in 2017.
The drug chapter segment of the Palmar Hyperhidrosis report encloses the detailed analysis of the Palmar Hyperhidrosis pipeline drug. It also helps understand the Palmar Hyperhidrosis clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
Treatment is focused entirely on managing symptoms and supporting the health and well-being of the affected child or adult. The management of Palmar Hyperhidrosis revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), etc. for the treatment of Palmar Hyperhidrosis in the pipeline.
The Palmar Hyperhidrosis market size is expected to increase at a significant CAGR during the study period (2017-2030). The United States accounts for the Palmar Hyperhidrosis market size, with USD 246.1 million in 2017.
This section focusses on the rate of uptake of the potential drugs in the Palmar Hyperhidrosis market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Palmar Hyperhidrosis market uptake by drugs, patient uptake by therapies, and sale of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Palmar Hyperhidrosis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Palmar Hyperhidrosis key players involved in developing targeted therapeutics.
The report covers the detailed information of Palmar Hyperhidrosis collaborations, acquisition and merger, licensing, patent details, and other information for Palmar Hyperhidrosis emerging therapies.
Approaching reimbursement, proactively, can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in Palmar HyperhIdrosis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Palmar Hyperhidrosis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
DelveInsight estimates an increase in Palmar hyperhidrosis Market Size during the study period, 2017-2030
Topical Medication, Affecting the larger population and Ease of treatment
Social and Professional Life, Lack of Etiology and Lack of Oral Medication
Currently, there are many key pharma players engaged in developing the drug for Palmar hyperhidrosis in monotherapy.
Prevalent Cases of Palmar hyperhidrosis, Diagnosed cases of Palmar hyperhidrosis, Palmar hyperhidrosis cases by Age and Severity-specific cases Palmar hyperhidrosis.
比較リスト
